The cardioprotective effects of levosimendan: preclinical and clinical evidence.
about
Levosimendan: current data, clinical use and future developmentLevosimendan: a cardiovascular drug to prevent liver ischemia-reperfusion injury?Comparison of Levosimendan versus Dobutamine in Patients with Moderate to Severe Left Ventricular Dysfunction Undergoing Off-pump Coronary Artery Bypass Grafting: A Randomized Prospective Study.Rescue of familial cardiomyopathies by modifications at the level of sarcomere and Ca2+ fluxes.Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarctionUse of levosimendan in patients with heart failure in different settings: case reports and treatment guidance.A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heartComparison of levosimendan and nitroglycerine in patients undergoing coronary artery bypass graft surgery.Large animal models of heart failure: a critical link in the translation of basic science to clinical practiceLevosimendan as treatment option in severe verapamil intoxication: a case report and review of the literaturePharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.Mitochondrial channels: ion fluxes and more.Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus.Early sensitization of myofilaments to Ca2+ prevents genetically linked dilated cardiomyopathy in mice.The effects of levosimendan exposure on oxidant/antioxidant status and trace element levels in the pulmonary artery of rats.Is levosimendan better than dobutamine in acute heart failure in patients on beta-blockade treatment? What is the evidence?The inodilator levosimendan as a treatment for acute heart failure in various settings.The clinical effects of levosimendan are not attenuated by sulfonylureas.Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery.Levosimendan improves hemodynamic status in critically ill patients with severe aortic stenosis and left ventricular dysfunction: an interventional study.Acute liver failure with extreme hyperbilirubinemia secondary to endocarditis-related severe mitral and tricuspid regurgitation: a challenge and an opportunity for surgeons.
P2860
Q24629274-E1A79081-5FB5-49A6-996B-4F82DB3E2ADAQ28533304-587DEA89-32EC-4D16-AD3C-10E4C4F8994CQ33613185-8E1170DC-7385-4D9F-AC8A-9BDBE72DB13FQ33787794-B2BB0FDE-C60D-4A0B-8148-0603C8BB20C6Q34139035-13420475-A9A1-4F52-ACA1-D576330F55F1Q35767495-741EEE11-0305-42EA-95E6-657989D9C811Q36735861-99AF6935-EC94-4D8B-86DF-0D695CE9BDF5Q36987964-024D1641-08DD-4675-A2FB-97A9FD7A4B3FQ37609687-18EA1557-C138-4154-B69E-1BB67C736A1CQ37784997-FAF151B7-55EB-4C4E-805E-8AFE7A8B2BC1Q38099679-E5A484B0-E957-4E20-9589-33A33375FFB9Q38201407-5AA1A2AB-1258-4D90-95B7-D9330F6F0187Q38208442-616AC71B-A9D6-4A16-8E27-BF208A0215B3Q38853345-2EC9D47A-5C9F-479A-B42B-B8006142D949Q41829049-73DC646A-A0EE-4D9F-B4BC-F4E6DA69F798Q43119695-58AAD2FE-DA96-4449-A5C7-77CE44A92F0EQ47097922-EA353B9C-8721-4212-803D-796DCF4B0086Q47212291-393C97CC-4DB1-4C78-A795-CECAAE0F049BQ47877301-53530CFE-6F4B-49DF-BAC7-ADD5D18955EEQ53511466-52E35FB7-1E30-4495-87C9-6416352869ABQ53833333-D28AB09A-8876-47E2-8D0B-7F0BF91C4FAA
P2860
The cardioprotective effects of levosimendan: preclinical and clinical evidence.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The cardioprotective effects of levosimendan: preclinical and clinical evidence.
@en
type
label
The cardioprotective effects of levosimendan: preclinical and clinical evidence.
@en
prefLabel
The cardioprotective effects of levosimendan: preclinical and clinical evidence.
@en
P1476
The cardioprotective effects of levosimendan: preclinical and clinical evidence.
@en
P2093
Zoltán Papp
P304
P356
10.1097/FJC.0B013E3180986230
P407
P577
2007-09-01T00:00:00Z